Atypical antipsychotics, also called second-generation antipsychotics, are a class of psychiatric medications used primarily to treat schizophrenia, bipolar disorder, and certain symptoms of depression and autism. They differ from older antipsychotics by acting on a broader set of brain receptors, which generally means fewer movement-related side effects but a higher risk of metabolic problems like weight gain and blood sugar changes.
How They Differ From Older Antipsychotics
The first antipsychotics, developed in the 1950s, worked almost entirely by blocking dopamine receptors in the brain. This effectively reduced hallucinations and delusions, but the same dopamine blockade in areas controlling movement caused serious side effects: muscle stiffness, tremors, restlessness, and involuntary movements that sometimes became permanent.
Atypical antipsychotics take a different approach. They still block dopamine receptors, but more weakly. Their defining feature is stronger activity at serotonin receptors, particularly the 5-HT2A receptor. This combination produces antipsychotic effects with a lower risk of movement problems and, in some cases, a faster onset of action. These drugs also interact with several other receptor systems, which contributes to their broader range of uses but also explains their varied side effect profiles.
Common Medications in This Class
Several atypical antipsychotics are available, each with a slightly different profile. The most widely prescribed include:
- Aripiprazole (Abilify): notable for working as a partial dopamine agonist rather than a pure blocker, giving it a more favorable metabolic profile
- Quetiapine (Seroquel): commonly used for bipolar depression and as an add-on for major depression
- Risperidone (Risperdal): one of the first atypicals developed, available in a long-acting injectable form
- Olanzapine (Zyprexa): effective but carries a higher risk of weight gain and metabolic changes
- Clozapine (Clozaril): reserved for treatment-resistant schizophrenia and requires regular blood monitoring due to a rare but serious risk of dangerously low white blood cell counts
- Ziprasidone (Zeldox): tends to be more weight-neutral than most others in this class
- Paliperidone (Invega): closely related to risperidone, available as a long-acting injection
What They’re Prescribed For
Schizophrenia is the most common reason these medications are prescribed, but several have approved uses well beyond psychosis. Quetiapine, aripiprazole, and olanzapine are all approved for bipolar disorder, covering manic episodes, mixed episodes, and in some cases maintenance therapy or bipolar depression. Aripiprazole and quetiapine are also approved as add-on treatments for major depressive disorder in adults who haven’t responded adequately to antidepressants alone.
Two medications in this class, aripiprazole and risperidone, are approved to treat irritability associated with autism in children. Clozapine occupies a unique position: it’s specifically indicated for schizophrenia that hasn’t responded to other treatments and for reducing suicide risk in people with schizophrenia.
How Quickly They Work
A persistent belief holds that antipsychotics take weeks to start working, but the evidence tells a different story. The largest improvements typically occur within the first one to two weeks of treatment. A meta-analysis of clinical trials found that the reduction in symptoms during the first week was nearly three times greater than the improvement seen during weeks three and four. By four weeks, roughly 68 to 70 percent of the total therapeutic benefit had already been achieved.
That said, the full effect does build over several weeks, and some symptoms respond faster than others. Agitation and sleep disturbance often improve within days, while more entrenched symptoms like social withdrawal or disorganized thinking take longer. If there’s no meaningful improvement after two to three weeks at an adequate dose, that’s typically a signal to reconsider the treatment plan rather than simply wait longer.
Movement Side Effects
One of the main reasons atypical antipsychotics were developed was to reduce the movement problems caused by older drugs. With first-generation antipsychotics, movement disorders occur in 50 to 75 percent of patients on long-term treatment. Atypical antipsychotics carry a meaningfully lower risk. The annual incidence of tardive dyskinesia, a condition involving involuntary repetitive movements that can become permanent, is about 3.9 percent with atypical agents compared to 5.5 percent with older drugs.
The risk isn’t zero, though. Among the atypicals, those that block dopamine more strongly (like risperidone at higher doses) are more likely to cause stiffness or restlessness than those with weaker dopamine blockade (like quetiapine or clozapine).
Metabolic Side Effects
The trade-off with atypical antipsychotics is a higher tendency to cause metabolic problems: weight gain, elevated blood sugar, and unfavorable cholesterol changes. These effects vary considerably across the class. Olanzapine and clozapine carry the highest metabolic risk, and about 40 percent of people with chronic schizophrenia taking these medications develop metabolic syndrome, a cluster of conditions that increases heart disease risk.
Quetiapine, risperidone, and asenapine fall in a moderate range. Ziprasidone, aripiprazole, and the newer drug lurasidone are generally the most metabolically neutral options. One important detail: about 25 percent of patients develop elevated blood sugar without gaining weight, and this can happen early in treatment, sometimes before any weight change is noticeable. This is why metabolic monitoring matters regardless of what the scale says.
Monitoring During Treatment
Clinical guidelines recommend a specific monitoring schedule for anyone starting an atypical antipsychotic. Before beginning treatment, you should have baseline measurements of weight, BMI, waist circumference, blood pressure, fasting blood sugar (or A1c), and a lipid panel including cholesterol and triglycerides. These tests are repeated at three months to catch early metabolic changes, then annually for as long as you’re taking the medication.
Clozapine requires additional monitoring. Because it carries a rare risk of severe neutropenia, a dangerous drop in infection-fighting white blood cells, patients need regular blood draws to check their absolute neutrophil count before starting and throughout treatment. The frequency of these blood draws depends on how long you’ve been on the medication and your results, but the monitoring is non-negotiable. Treatment may need to be paused or stopped if counts drop too low.
A New Direction: Cobenfy
In 2024, the FDA approved Cobenfy, the first antipsychotic for schizophrenia that works through an entirely different mechanism. Instead of targeting dopamine receptors, it acts on cholinergic receptors, a system involved in memory and attention. In two five-week clinical trials, Cobenfy produced meaningful reductions in schizophrenia symptoms compared to placebo.
Because it doesn’t block dopamine, Cobenfy avoids the movement-related side effects and metabolic disruption associated with traditional and atypical antipsychotics. Its side effect profile looks quite different: nausea, indigestion, constipation, and increased heart rate are the most common issues. It’s not suitable for everyone, particularly people with kidney or liver disease, urinary retention, or certain eye conditions. But its approval represents the first genuinely new approach to treating schizophrenia in decades, and it may eventually expand the options for people who can’t tolerate existing medications.